Control Bionics Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive CBL News and Ratings via Email

Sign-up to receive the latest news and ratings for Control Bionics and its competitors with MarketBeat's FREE daily newsletter.

About Control Bionics

Control Bionics Limited designs, manufactures, and sells wireless wearable electromyography based augmentative and alternative communication technologies that allow users to operate and communicate through a computer using their thoughts and neuroelectric signals. It offers Eye Control Duo, an integrated eye tracking device for those living with paralysis and loss of speech; NeuroNode Trilogy, a solution for those living with paralysis and loss of speech; and Control Bionics Complete Communication System, an out of the box solution for those living with paralysis and loss of speech. The company also provides support and warranty services. The company's products are used by people suffering from diseases, such as motor neuron diseases, amyotrophic lateral sclerosis, cerebral palsy, multiple sclerosis, and spinal cord injuries. It operates in Australia, the United States, Japan, and internationally. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Surrey Hills, Australia.


No headlines for this company have been tracked by

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Control Bionics (ASX:CBL) Frequently Asked Questions

What stocks does MarketBeat like better than Control Bionics?

Wall Street analysts have given Control Bionics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Control Bionics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Control Bionics' key executives?

Control Bionics' management team includes the following people:
  • Mr. Robert William Wong, CEO & Board Member
  • Mr. Peter Shann Ford, Founder, Board Member & Director of Innovation
  • Mr. Neale Java, Chief Financial Officer
  • Mr. Tony Mackzum, Fin. & Operations Director
  • Mr. James Schorey, Chief Technology Officer
  • Ms. Meagan Koeneman, Sales Director
  • Mr. Brett Crowley B.Com., C.A., BCom, DipLaw, CA, Company Sec. & Board Member (Age 64)

Who are some of Control Bionics' key competitors?

What is Control Bionics' stock symbol?

Control Bionics trades on the ASX under the ticker symbol "CBL."

How much money does Control Bionics make?

Control Bionics has a market capitalization of $0.00 and generates $3.20 million in revenue each year.

How many employees does Control Bionics have?

Control Bionics employs 25 workers across the globe.

What is Control Bionics' official website?

The official website for Control Bionics is

How can I contact Control Bionics?

The company can be reached via phone at 61 3 9897 3576.

This page was last updated on 7/29/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.